Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yarrow BioscienceYARW -2.78%13 EBITDA Margin % is -3,197.94% as of Jun. 2026. GuruFocus rates YARW with a GF Score™ of 13/100. Among 947 Biotechnology companies, Yarrow Bioscience ranks worse than 92.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Yarrow Bioscience's EBITDA for the
three
months ended in Jun. 2026 was $-3.10 Mil. Yarrow Bioscience's Revenue for the
three
months ended in Jun. 2026 was $0.10 Mil. Therefore, Yarrow Bioscience's EBITDA margin for the quarter that ended in Jun. 2026 was -3,197.94%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Yarrow Bioscience EBITDA Margin % Related Terms
Yarrow Bioscience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Yarrow Bioscience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience EBITDA Margin % Chart
Yarrow Bioscience Annual Data
Trend
Dec25
EBITDA Margin %
0.00
Yarrow Bioscience Quarterly Data
Jun25
Dec25
Mar26
Jun26
EBITDA Margin %
-10,930.43
0.00
0.00
-3,197.94
YARW vs CGTX, RANI, VRCA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Yarrow Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yarrow Bioscience EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Yarrow Bioscience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a EBITDA Margin % of -3,197.94% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Yarrow Bioscience and its competitors. According to the industry distribution chart, Yarrow Bioscience ranks #874 out of 947 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Yarrow Bioscience's EBITDA Margin % too high?
Yarrow Bioscience's current EBITDA Margin % is -3,197.94%. Based on the distribution chart, Yarrow Bioscience ranks #874 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's EBITDA Margin % compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #874 out of 947 companies for EBITDA Margin %. This places Yarrow Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Yarrow Bioscience and its competitors. Yarrow Bioscience's current EBITDA Margin % is -3,197.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current EBITDA Margin % of -3,197.94%. The current EBITDA Margin % is -3,197.94%. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current EBITDA Margin % is -3,197.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
